Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Novo Nordisk A/S
Darren K McGuire; Nikolaus Marx; Sharon L Mulvagh; John E Deanfield; Silvio E Inzucchi; Rodica Pop-Busui; Johannes F E Mann; Scott S Emerson; Neil R Poulter; Mads D M Engelmann; Maria Sejersten Ripa; G Kees Hovingh; Kirstine Brown-Frandsen; Stephen C Bain; Matthew A Cavender; Mette Gislum; Jens-Peter David; John B Buse; SOUL Study Group
Department of Biostatistics, University of Washington, Seattle.